- Merck’s KEYTRUDA® plus trastuzumab and chemotherapy significantly improved overall survival in HER2-positive advanced gastric or GEJ adenocarcinoma patients compared to trastuzumab and chemotherapy alone.
Sat Sep 14 06:17:01 -0000 2024 UTC– Merck & Co. announced that KEYTRUDA with Trastuzumab and Chemotherapy improves survival in HER2-positive gastric cancer patients compared to Trastuzumab and Chemotherapy alone.
ESMO
The new data were presented at the European Society for Medical Oncology (ESMO) Congress 2024 and are also published in the New England Journal of Medicine.
US Status
In the U.S., KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
EU Status
In August 2023, the European Commission (EC) approved KEYTRUDA in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma in adults.
Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:
About Lisa
Subscribe to Lisa’s Newsletter today!
Keep Up: Nobot.News Launches Breaking Newsletter
Read more Business News as it happens!
Business